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Summary Zonisamide is a new type of benzisoxazole derivative, ﬁrst marketed in
Japan in 1989. This study analyzed: (1) the drug’s efﬁcacy by seizure and epilepsy type
in a total of 1008 patients treated during the development of zonisamide in Japan; (2)
the effectiveness of zonisamide for 726 newly-diagnosed patients treated with zon-
isamide postmarketing; and (3) 50 patients with generalized epilepsies and epileptic
syndromes (idiopathic generalized epilepsies, symptomatic generalized epilepsies,
Lennox–Gastaut syndrome, Doose syndrome, and West syndrome), and 19 patients
with undetermined epilepsies and speciﬁc syndromes (refractory grand mal in child-
hood, severe myoclonic epilepsy in infancy, other undetermined epilepsy, familial
essential myoclonic epilepsy, and mitochondrial encephalomyopathy with ragged-red
ﬁbers). Analysis of study results showed that among all patients treated, zonisamide
was highly effective for the treatment of idiopathic generalized epilepsy, temporal
lobe epilepsy, and other partial epilepsies. The compound was also effective for other
symptomatic generalized epilepsies. In 50 patients with generalized epilepsies, and
19 with undetermined epilepsies and speciﬁc syndromes, seizure frequency was re-
duced by >50% with monotherapy or two-drug therapy with zonisamide. Zonisamide
was effective not only for partial epilepsies and generalized epilepsies but also for
undetermined epilepsies and speciﬁc syndromes such as myoclonus epilepsy.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Zonisamide is a benzisoxazole derivative, chem-
ically unrelated to existing antiepileptic drugs
(AEDs).1 Zonisamide’s mechanism of action is ap-
parently based on its ability to block voltage-
sensitive sodium and T-type calcium channels.2—4
In view of its potential as a broad-spectrum AED,
zonisamide was studied extensively in pre- and
postmarketing trials in Japan. Pooled efﬁcacy data
from 1008 patients in Phase II and III studies,5—8
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as well as data from a postmarketing study of 726
newly-diagnosed patients [internal report, Dainip-
pon Pharmaceutical Company Ltd.], are presented
in this paper. In addition, experience with the use
of this agent in smaller patient cohorts at the Na-
tional Epilepsy Center, Shizuoka, sheds further light
on the efﬁcacy of zonisamide.
Premarketing studies
Pooled efﬁcacy data on 1008 patients from con-
trolled and uncontrolled Phase II and III studies con-
ducted over a 7-year period at 56 centers in Japan
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Table 1 Age and dose distribution among patients
taking zonisamide (N = 1008).
Age range; years (n) Mean dose; mg/kg (range)
≤1 (12) 8.6 (2.8—21.4)
2—6 (99) 8.8 (0.8—30.4)
7—15 (292) 7.1 (0.7—20.2)
≥16 (605) 5.9 (1.1—17.7)
were analyzed with respect to epilepsy and seizure
type.
The efﬁcacy rate was deﬁned as the percentage
of patients whose seizure frequency was reduced
by 50% or more from baseline by adjunctive therapy
with zonisamide in uncontrolled trials or compared
with carbamazepine or valproate in controlled
trials.
The age distribution of the patients and mean
dose per group are shown in Table 1. Fig. 1 shows
the efﬁcacy of zonisamide in relation to the num-
ber of concomitant AEDs. Of 55 patients treated
with zonisamide alone, the efﬁcacy rate was 72%.
Figure 1 Number of concomitant AEDs and efﬁcacy of zonisamide (ZNS).
Figure 2 Efﬁcacy of zonisamide therapy by epilepsy type among patients with partial epilepsies.
This dropped to 52, 48, and 43% in the patients
treated with 1, 2, or 3 additional AEDs. These data
suggest that the smaller the number of concomi-
tant AEDs, the greater the efﬁcacy of zonisamide.
The concomitant AEDs were, in decreasing or-
der of use, carbamazepine, phenytoin, valproic
acid, phenobarbital, clonazepam, primidone, ac-
etazolamide, nitrazepam, sulthiame, and etho-
suximide.
Partial epilepsies accounted for nearly 70% of all
epilepsy types in the population studied. Of 673
patients with partial epilepsy, 64% had temporal
lobe epilepsy, 33% had non-temporal lobe epilepsy,
and 3% had unclassiﬁed partial epilepsy. Efﬁcacy
rates ranged from 51 to 57% in patients with partial
epilepsies as shown in Fig. 2.
Among 282 patients with generalized epilepsies,
efﬁcacy rates ranged from 22 to 66% (Table 2). Thus,
zonisamide appeared to be effective not only for
partial epilepsies, but also to some extent for gen-
eralized epilepsies.
Analysis of data by seizure type in 954 patients
with identiﬁed seizures revealed that zonisamide
was effective in all types of partial seizures, and to
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Table 2 Efﬁcacy of zonisamide therapy by epilepsy
type among patients with generalized epilepsies
(N = 282).
Epilepsy type n Efﬁcacy
rate (%)
Idiopathic generalized 41 66
Lennox—Gastaut syndrome 132 32
West syndrome 9 22
Symptomatic generalizeda 100 47
a Other than West and Lennox—Gastaut syndromes.
Table 3 Efﬁcacy of zonisamide therapy by seizure
type.
Seizure type n Efﬁcacy
rate (%)
Partial
Simple partial 63 57
Simple partial followed
by complex partial
82 50
Complex partial 362 50
Partial onset generalized
tonic—clonic
168 60
Generalized
Generalized tonic—clonic 46 59
Generalized tonic 74 26
Absence (typical and atypical) 13 62
Atonic 10 50
Myoclonic 7 43
Combined 129 41
varying degrees in all types of generalized seizures
(Table 3). Partial seizures accounted for 70% of all
seizure types.
Data on the efﬁcacy rates in relation to seizure
frequency in 935 patients with identiﬁed seizure
Figure 3 Relation between seizure frequency and zonisamide efﬁcacy.
frequency show that the addition of zonisamide was
effective in 42% of patients having daily seizures,
as shown in Fig. 3. The lower the seizure frequency,
the higher the efﬁcacy of zonisamide.
The most frequent adverse event associated with
zonisamide therapy was drowsiness (24%), followed
by ataxia (13%), loss of appetite (11%), gastroin-
testinal symptoms (7%), decrease of spontaneity
(6%), and slowing of mental activity (5%).
Postmarketing experience
Zonisamidemonotherapy in newly-diagnosed
patients in a retrospective study
One large postmarketing trial studied zonisamide
monotherapy in 736 patients newly diagnosed
with epilepsy. Again, the efﬁcacy of zonisamide
was deﬁned as the percentage of patients that
demonstrated a 50% or greater reduction in seizure
frequency compared to the patient’s seizure fre-
quency before administration of zonisamide, to the
total number of patients in each group. The mean
doses were 5.47 ± 2.62mg/kg per day in patients
under 16 years, and 248.8 ± 102.4mg per day in
patients age 16 or older. The mean concentration
was 14.62 ± 8.18g/mL in patients under age 16,
and 15.83 ± 8.98g/mL in patients age 16 or older.
The mean duration of zonisamide treatment was
334.5 ± 244.7 days.
Among 359 patients with partial epilepsies, ef-
fective control of seizures was achieved with zon-
isamide monotherapy in 79% of 99 newly-diagnosed
patients with temporal lobe epilepsy, 84% of 243
with non-temporal lobe epilepsies, and 88% of 17
with unclassiﬁed partial epilepsies. Zonisamide
monotherapy was effective in controlling seizures
in 50—100% of 367 patients with newly-diagnosed
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Table 4 Efﬁcacy of ZNS monotherapy among pa-
tients newly diagnosed with generalized epilepsies
and undetermined epilepsies.
Epilepsy type n Efﬁcacy rate (%)
Idiopathic generalized 217 90
West syndrome 4 50
Lennox—Gastaut 2 100
Symptomatic generalizeda 120 93
Unclassiﬁed 24 92
a Other than West and Lennox—Gastaut syndromes.
Table 5 Efﬁcacy of zonisamide monotherapy among
newly-diagnosed patients according to seizure type.
Seizure type n Efﬁcacy
rate (%)
Partial
Simple partial 128 82
Complex partial 179 80
Partial onset generalized
tonic—clonic
149 82
Generalized
Tonic—clonic 257 93
Tonic 54 93
Absence 34 85
Myoclonic 6 83
Atonic 1 0
generalized and other undetermined epilepsies
(Table 4).
The efﬁcacy rates of zonisamide monotherapy by
seizure type in 726 newly-diagnosed patients with
partial or generalized seizures were also favorable
(Table 5).
Clinical experience at the National Epilepsy
Center
A cohort of 50 patients with generalized epilepsies
treated with zonisamide and 1 additional concomi-
tant AED was studied. Of these patients, 6 and
27 had idiopathic and symptomatic generalized
epilepsies, respectively; 2 had Lennox—Gastaut
syndrome, 14 had West syndrome, and 1 had Doose
syndrome. A further cohort of 19 patients with
undetermined epilepsies and speciﬁc syndromes
was studied. Of these, seven had refractory child-
hood grand mal seizures, ﬁve had severe myoclonic
epilepsy in infancy, four had other undetermined
epilepsy, two had familial essential myoclonic
epilepsy, and one had mitochondrial encephalomy-
opathy with ragged-red ﬁbers.
In both these cohorts, when zonisamide was ad-
ministered alone or with one other AED for more
than 6 months, seizure frequency was reduced by
50% or more for more than 6 months. All 14 chil-
dren with West syndrome showed seizure control
for 3—5 months on zonisamide monotherapy or zon-
isamide plus one other AED (mostly valproate). Four
of these patients (two on monotherapy and two on
zonisamide plus one other AED) had experienced
complete freedom from seizures for more than 12
months.
Case study 1
Following is a case study of a 6-month-old boy with
West syndrome treated with zonisamide. There
were no abnormal ﬁndings in the ﬁrst few months
after birth. At age 5 months, it was noted that
the baby’s body twitched momentarily just as he
was falling asleep. Two weeks later, seizures oc-
curred in series. Each series consisted of 10—30
spasms and occurred 3—4 times per day. The elec-
troencephalogram (EEG) showed hypsarrhythmia.
Computerized axial tomography and magnetic res-
onance imaging revealed no speciﬁc ﬁndings. Vi-
tamin B6 (30—50mg/kg per day) was administered
for 1 week, but proved ineffective. Therefore, val-
proate was started and Vitamin B6 was tapered off.
Although the dose of valproate was increased up
to 350mg per day and correlated with serum con-
centrations of up to 137g/mL, it had no effect on
seizure occurrence. Consequently, zonisamide was
started as adjunctive therapy and the incidence
of seizures began to decrease. Once the dose of
zonisamide was increased to 55mg per day, the
seizures completely disappeared. EEG also showed
signs of marked improvement. The serum concen-
tration of zonisamide was maintained between
12 and 16g/mL. No further seizures have been
observed during the past year of zonisamide.
Case study 2
Following is a case study of an 8-year-old girl di-
agnosed with Lennox—Gastaut syndrome treated
with zonisamide. She had a history of myoclonic
and tonic seizures at the age of 26 months. At age
5, she presented with atypical absence seizures.
After treatment with valproate, all seizures disap-
peared. However, at age 8, tonic seizures recurred.
Both before and at this time, serum concentra-
tion of valproate was 103g/mL. EEG after seizure
recurrence showed frequent slow spike-and-wave
complexes and fast rhythm.
Valproate was discontinued and zonisamide initi-
ated at a dose of 100mg per day. After 1 month,
tonic seizures ceased and EEG showed no epileptic
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discharges. The seizures were still controlled 19
months later and the patient had experienced no
adverse reactions.
Case study 3
In this case study, a 14-month-old girl with symp-
tomatic generalized epilepsy presented with a his-
tory of myoclonic seizures that developed at 1 year
of age. Seizures occurred 20—30 times a day. EEG
showed frequent generalized diffused poly-spikes.
Sodium valproate at a dose of 400mg daily was
administered without effect. Phenytoin was added
but no remarkable improvement was seen. Zon-
isamide was added at a dose of 70mg per day, which
was ineffective. The dose was increased to 120mg
per day, after which the seizures decreased and
stopped. Valproate and phenytoin were then dis-
continued. Monotherapy with zonisamide was con-
tinued and the seizures disappeared with a serum
concentration of 26—32g/mL. The EEG returned
to normal.
Conclusion
Because zonisamide is approved in Japan for use in
monotherapy in children as well as adults, exami-
nation of data from pre- and postmarketing studies
conducted in that country provides insight into the
use of zonisamide in clinical practice.
Experience with zonisamide in Japan suggests
that it has a broad spectrum of activity, demon-
strating improvements in seizure rates across a
range of epilepsy and seizure types in infants, chil-
dren, and adults. Administered as monotherapy
or in combination with one or more other AEDs,
zonisamide consistently reduces the frequency of
seizures by 50% or more, and offers long-term ef-
ﬁcacy. Zonisamide is an important addition to the
drugs available for the management of epilepsy.
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